Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study predicting the response to induction chemotherapy of three courses of Docetaxel, Cisplatin and 5-Fluorouracil, inoperable squamous cell carcinoma of the upper aero-digestive tract stages T3 or T4, any N, MO, by micro analysis chip-transcriptional changes induced by the first tumor cure. [Etude de prédiction de la réponse à une chimiothérapie d'induction de 3 cures de Docetaxel, Cisplatine et 5-Fluorouracile, des carcinomes épidermoïdes des voies aéro-digestives supérieures de stades T3 ou T4, tout N, MO, inopérables, par analyse en micro-puces des modifications transcriptionnelles tumorales induites par la première cure]

Next Previous
Trial Profile

Study predicting the response to induction chemotherapy of three courses of Docetaxel, Cisplatin and 5-Fluorouracil, inoperable squamous cell carcinoma of the upper aero-digestive tract stages T3 or T4, any N, MO, by micro analysis chip-transcriptional changes induced by the first tumor cure. [Etude de prédiction de la réponse à une chimiothérapie d'induction de 3 cures de Docetaxel, Cisplatine et 5-Fluorouracile, des carcinomes épidermoïdes des voies aéro-digestives supérieures de stades T3 ou T4, tout N, MO, inopérables, par analyse en micro-puces des modifications transcriptionnelles tumorales induites par la première cure]

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 03 Jul 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top